来曲唑或他莫昔芬联合用药在乳腺癌患者生育力保存中的比较
该回顾性队列研究分析了2000至2022年间在两个三级中心接受生育力保存的新诊断乳腺癌患者,比较FSH联合来曲唑或他莫昔芬的结局。来曲唑组FSH剂量更高、刺激时间更短、峰值雌二醇和子宫内膜厚度更低,但获卵数、冷冻卵母细胞数、胚胎数、卵母细胞成熟率及受精率两组相当。多因素分析未发现治疗方案与获卵数或成熟率显著相关。
要点
- 来曲唑组FSH总量更高(3970±2027 IU vs 2839±1052 IU,P<0.001)但刺激时间更短(9.7 vs 10.5天,P<0.001)。
- 来曲唑组峰值雌二醇(1508±1242 pmol/l vs 8760±5771 pmol/l,P<0.001)和子宫内膜厚度(8.1±2.4 mm vs 9.5±2.6 mm,P<0.001)均低于他莫昔芬组。
- 两组每周期获卵数、冷冻卵母细胞数、胚胎数、成熟率及受精率均无显著差异。
核心结论
- 来曲唑或他莫昔芬与FSH联合用于乳腺癌患者生育力保存,获卵数、冷冻卵母细胞和胚胎数、卵母细胞成熟率及受精率相似。
研究设计与样本
- 回顾性队列研究,纳入2000至2022年间在两个三级中心接受生育力保存的新诊断乳腺癌患者,共354个周期(n=290),其中来曲唑组215个周期,他莫昔芬组139个周期。
主要发现
- 来曲唑组FSH总剂量3970±2027 IU,他莫昔芬组2839±1052 IU(P<0.001);刺激持续时间来曲唑组9.7天,他莫昔芬组10.5天(P<0.001)。
- 来曲唑组峰值雌二醇1508±1242 pmol/l,他莫昔芬组8760±5771 pmol/l(P<0.001);子宫内膜厚度来曲唑组8.1±2.4 mm,他莫昔芬组9.5±2.6 mm(P<0.001)。
- 每周期平均获卵数来曲唑组13.6±11.7,他莫昔芬组14.7±9.8(P=0.06)。
- 严格卵母细胞冷冻周期中,每周期冷冻卵母细胞数来曲唑组(122例)11±8.4,他莫昔芬组(46例)12.1±7.9(P=0.21);胚胎冷冻周期中,来曲唑组(71周期)6.2±7.1,他莫昔芬组(76周期)7.0±5.3(P=0.12)。
- 卵母细胞成熟率来曲唑组86±17%,他莫昔芬组83±14%(P=0.06);IVF受精率分别为62±26%和63±26%(P=0.8),ICSI受精率分别为71±28%和76±23%(P=0.30);多因素分析未发现治疗方案与获卵数或成熟率显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Do fertility preservation outcomes differ between newly diagnosed breast cancer patients stimulated with FSH and tamoxifen compared with FSH and Letrozole? DESIGN: Retrospective cohort study of fertility preservation treatments in newly diagnosed breast cancer patients at two tertiary centres (2000-2022). RESULTS: Patients that underwent 354 fertility preservation cycles participated in the study (n = 290): letrozole (n = 215) and tamoxifen (n = 139). Treatments with letrozole were associated with higher FSH dosages (3970 ± 2027 IU versus 2839 ± 1052 IU, P < 0.001) but were of shorter duration (9.7 versus 10.5 days, P < 0.001). The letrozole group achieved lower peak oestradiol levels (1508 ± 1242 pmol/l versus 8760 ± 5771 pmol/l, P < 0.001) and endometrial thickness (8.1 mm ± 2.4 versus 9.5 ± 2.6 mm, P < 0.001). Mean oocyte number retrieved per cycle was comparable between the groups (13.6 ± 11.7 with letrozole versus 14.7 ± 9.8 with tamoxifen, P = 0.06). In 122 patients taking letrozole and 46 patients taking tamoxifen who underwent strictly oocyte cryopreservation cycles, the mean number of cryopreserved oocytes per cycle was comparable (11 ± 8.4 versus 12.1 ± 7.9, P = 0.21). Similar results were obtained in embryo cryopreservation: letrozole (n = 71 cycles) versus tamoxifen (n = 76 cycles) (6.2 ± 7.1 versus 7.0 ± 5.3, respectively, P = 0.12). Oocyte maturation rates among strictly oocyte preservation cycles were comparable (86 ± 17% with letrozole versus 83 ± 14% with tamoxifen, P = 0.06), as were fertilization rates in embryo cryopreservation cycles (IVF: 62 ± 26% versus 63 ± 26%, P = 0.8; intracytoplasmic sperm injection: 71 ± 28% versus 76 ± 23%, P = 0.30) with letrozole and tamoxifen, respectively. Multivariate analysis, controlling for potential confounders showed no significant correlations between treatment type and the number of retrieved oocytes or maturation rates. CONCLUSION: Letrozole or tamoxifen co-administration with FSH yielded similar number of retrieved and cryopreserved oocytes and embryos, as well as similar oocyte maturation and fertilization rates.
引用
- Lifshitz D, Ben-Haroush A, Meirow D, et al. Letrozole or tamoxifen co-administration during fertility preservation for patients affected by breast cancer. Reprod Biomed Online. 2025. PMID: 40680551. doi:10.1016/j.rbmo.2025.104878
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。